Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Park, Hana ^a   Park, Jun Yong ^b  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHLOROTRIANISENE; DECARBOXYPROTHROMBIN; IODINATED POPPYSEED OIL; PROTHROMBIN; SORAFENIB; VITAMIN K GROUP; AFP PROTEIN, HUMAN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; OVERALL SURVIVAL; PATIENT MONITORING; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; GENETICS; LIVER TUMOR; META ANALYSIS; METABOLISM; PATHOLOGY; PROGNOSIS; SURVIVAL;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VITAMIN K;

EID: 84896079845     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/310427     Document Type: Article

References (36)

1. Han K.-H., Ahn S. H., How to predict HCC development in patients with chronic B viral liver disease? Intervirology 2005 48 1 23 28 2-s2.0-17244382334 10.1159/000082091 (Pubitemid 40529207)
2. Llovet J. M., di Bisceglie A. M., Bruix J., Kramer B. S., Lencioni R., Zhu A. X., Sherman M., Schwartz M., Lotze M., Talwalkar J., Gores G. J., Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute 2008 100 10 698 711 2-s2.0-44449085884 10.1093/jnci/djn134
3. Eisenhauer E. A., Therasse P., Bogaerts J., Schwartz L. H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009 45 2 228 247 2-s2.0-57849117384 10.1016/j.ejca.2008.10.026
4. Furuse J., Ishii H., Nakachi K., Suzuki E., Shimizu S., Nakajima K., Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Science 2008 99 1 159 165 2-s2.0-36949033865 10.1111/j.1349-7006.2007. 00648.x (Pubitemid 350239045)
5. Kim B. K., Ahn S. H., Seong J. S., Park J. Y., Kim D. Y., Kim J. K., Lee D. Y., Lee K. H., Han K.-H., Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver International 2011 31 3 369 376 2-s2.0-79551521168 10.1111/j.1478-3231.2010.02368.x
6. Johnson P. J., The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clinics in Liver Disease 2001 5 1 145 159 2-s2.0-0035143887 (Pubitemid 32118643)
7. Inagaki Y., Tang W., Makuuchi M., Hasegawa K., Sugawara Y., Kokudo N., Clinical and molecular insights into the hepatocellular carcinoma tumour marker des- γ -carboxyprothrombin. Liver International 2011 31 1 22 35 2-s2.0-78650088633 10.1111/j.1478-3231.2010.02348.x
8. Bloomer J. R., Waldmann T. A., McIntire K. R., Klatskin G., alpha-fetoprotein in noneoplastic hepatic disorders. Journal of the American Medical Association 1975 233 1 38 41 2-s2.0-0016845384 10.1001/jama.233.1.38
9. Bloomer J. R., Waldmann T. A., McIntire K. R., Klatskin G., Serum α fetoprotein in patients with massive hepatic necrosis. Gastroenterology 1977 72 3 479 482 2-s2.0-0017334247 (Pubitemid 8036726)
10. Hamamura K., Shiratori Y., Shiina S., Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000 88 7 1557 1564 (Pubitemid 30183140)
11. Koike Y., Shiratori Y., Sato S., Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001 91 3 561 569 (Pubitemid 32105702)
12. Zhou L., Liu J., Luo F., Serum tumor markers for detection of hepatocellular carcinoma. World Journal of Gastroenterology 2006 12 8 1175 1181 2-s2.0-33645523023
13. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M., Serum markers of hepatocellular carcinoma. Digestive Diseases and Sciences 2010 55 10 2744 2755 2-s2.0-77957892168 10.1007/s10620-010-1184-7
14. Park H., Kim S. U., Park J. Y., Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver International 2013 10.1111/liv.12274
15. Kishi K., Sonomura T., Mitsuzane K., Nishida N., Kimura M., Satoh M., Yamada R., Kodama N., Kinoshita M., Tanaka H., Iseki Y., Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Radiation Medicine 1992 10 5 189 195 2-s2.0-0026488098
16. Aoyagi Y., Oguro M., Yanagi M., Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996 77 9 1781 1786 (Pubitemid 26125176)
17. Kokudo N., Makuuchi M., Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. Journal of Gastroenterology 2009 44 19 119 121 2-s2.0-58849159660 10.1007/s00535-008-2244-z
18. Nakagawa T., Seki T., Shiro T., Clinicopathologic significance of protein induced vitamin K absence or antagonist II and α-fetoprotein in hepatocellular carcinoma. International Journal of Oncology 1999 14 2 281 286 2-s2.0-0033074462
19. Yamashita F., Tanaka M., Satomura S., Tanikawa K., Prognostic significance of Lens culinaris agglutinin A-reactive α-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996 111 4 996 1001 2-s2.0-0029838117 (Pubitemid 26327602)
20. Chon Y. E., Choi G. H., Lee M. H., Kim S. U., Kim D. Y., Ahn S. H., Kim K. S., Choi J. S., Han K.-H., Chon C. Y., Park J. Y., Combined measurement of preoperative α-fetoprotein and des- γ -carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. International Journal of Cancer 2012 131 10 2332 2341 2-s2.0-84858966802 10.1002/ijc.27507
21. Kang S. H., Kim do Y., Jeon S. M., Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. European Journal of Gastroenterology & Hepatology 2012 24 7 849 856 10.1097/MEG.0b013e3283535c34
22. Lee Y. K., Kim S. U., Kim do Y., Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013 13, article 5 10.1186/1471-2407-13-5
23. Lee M. H., Kim S. U., Kim D. Y., Ahn S. H., Choi E. H., Lee K. H., Lee D. Y., Seong J., Han K.-H., Chon C. Y., Park J. Y., Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2012 27 2 313 322 2-s2.0-84856154899 10.1111/j.1440-1746.2011.06867.x
24. Toyoda H., Kumada T., Tada T., Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy. Journal of Hepatology 2012 57 6 1251 1257 10.1016/j.jhep.2012.07.018
25. Nanashima A., Taura N., Abo T., Ichikawa T., Sakamoto I., Nagayasu T., Nakao K., Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival. Digestive Diseases and Sciences 2011 56 10 3086 3100 2-s2.0-80054724610 10.1007/s10620-011-1796-6
26. Yamamoto K., Imamura H., Matsuyama Y., Hasegawa K., Beck Y., Sugawara Y., Makuuchi M., Kokudo N., Significance of alpha-fetoprotein and des- γ -carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Annals of Surgical Oncology 2009 16 10 2795 2804 2-s2.0-73349113221 10.1245/s10434-009-0618-y
27. Masuda T., Beppu T., Horino K., Komori H., Hayashi H., Okabe H., Otao R., Horlad H., Ishiko T., Takamori H., Kikuchi K., Baba H., Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. Journal of Surgical Oncology 2010 102 5 490 496 2-s2.0-77957364703 10.1002/jso.21451
28. Nanashima A., Sumida Y., Tobinaga S., Shibata K., Shindo H., Obatake M., Shibasaki S., Ide N., Nagayasu T., Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis. HPB 2006 8 2 137 141 2-s2.0-33646115434 10.1080/13651820500273475
29. Park W. H., Shim J. H., Han S. B., Clinical utility of des-gamma-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Journal of Vascular and Interventional Radiology 2012 23 7 927 936 10.1016/j.jvir.2012.04.021
30. Kuzuya T., Asahina Y., Tsuchiya K., Tanaka K., Suzuki Y., Hoshioka T., Tamaki S., Kato T., Yasui Y., Hosokawa T., Ueda K., Nakanishi H., Itakura J., Takahashi Y., Kurosaki M., Izumi N., Early decrease in α-fetoprotein, but not des- γ -carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011 81 3-4 251 258 2-s2.0-81555231534 10.1159/000334454
31. Nakazawa T., Hidaka H., Takada J., Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. European Journal of Gastroenterology & Hepatology 2013 25 6 683 689 10.1097/MEG.0b013e32835d913b
32. Riaz A., Memon K., Miller F. H., Nikolaidis P., Kulik L. M., Lewandowski R. J., Ryu R. K., Sato K. T., Gates V. L., Mulcahy M. F., Baker T., Wang E., Gupta R., Nayar R., Benson A. B. III, Abecassis M., Omary R., Salem R., Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. Journal of Hepatology 2011 54 4 695 704 2-s2.0-79952696628 10.1016/j.jhep.2010.10.004
33. Arnold M. M., Kreel L., Wallace A. C., Li A. K. C., Distribution of lipiodol and evidence for tumor necrosis in hepatocellular carcinoma. American Journal of Clinical Pathology 1992 97 3 405 410 2-s2.0-0026587919
34. Yamamoto K., Imamura H., Matsuyama Y., Kume Y., Ikeda H., Norman G. L., Shums Z., Aoki T., Hasegawa K., Beck Y., Sugawara Y., Kokudo N., AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. Journal of Gastroenterology 2010 45 12 1272 1282 2-s2.0-78651317489 10.1007/s00535-010- 0278-5
35. Nakazawa T., Adachi S., Kitano M., Isobe Y., Kokubu S., Hidaka H., Ono K., Okuwaki Y., Watanabe M., Shibuya A., Saigenji K., Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 2008 73 1-2 90 97 2-s2.0-41549135296 10.1159/000120996 (Pubitemid 351465606)
36. Murata K., Suzuki H., Okano H., Oyamada T., Yasuda Y., Sakamoto A., Hypoxia-induced des- γ -carboxy prothrombin production in hepatocellular carcinoma. International Journal of Oncology 2010 36 1 161 170 2-s2.0-74549217434 10.3892/ijo-00000487